


Ask a doctor about a prescription for EXFORGE HCT 10 mg/160 mg/25 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Exforge HCT 5mg/160mg/12.5mg film-coated tablets
Exforge HCT 10mg/160mg/12.5mg film-coated tablets
Exforge HCT 5mg/160mg/25mg film-coated tablets
Exforge HCT 10mg/160mg/25mg film-coated tablets
Exforge HCT 10mg/320mg/25mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Exforge HCT tablets contain three substances called amlodipine, valsartan, and hydrochlorothiazide. All these substances help to control high blood pressure.
As a result of the three mechanisms, the blood vessels relax and blood pressure decreases.
Exforge HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan, and hydrochlorothiazide and who can benefit from taking a single tablet containing the three substances.
Do not take Exforge HCT
Do not take Exforge HCT and inform your doctor if you are affected by any of the above.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Exforge HCT
Your doctor may check your kidney function, blood pressure, and electrolyte levels (e.g., potassium) in your blood at regular intervals.
See also the information under the heading “Do not take Exforge HCT”.
Tell your doctor if you are affected by any of the above.
Children and adolescents
Exforge HCT is not recommended for use in children and adolescents under 18 years of age.
Elderly (65 years and older)
Exforge HCT can be used in people 65 years and older at the same dose as used in other adults and in the same way as they have already taken the three substances called amlodipine, valsartan, and hydrochlorothiazide. The blood pressure of elderly patients should be checked periodically, especially those taking the maximum dose of Exforge HCT (10 mg/320 mg/25 mg).
Other medicines and Exforge HCT
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. Your doctor may need to change your dose and/or take other precautions. In some cases, you may need to stop taking one of the medicines. This is especially important if you are using any of the following medicines:
Do not take with:
Should be used with caution with:
Taking Exforge HCT with food, drinks, and alcohol
People who have been prescribed Exforge HCT should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active substance amlodipine in the blood, which can cause an unpredictable increase in the blood pressure-lowering effects of Exforge HCT. Consult your doctor before drinking alcohol. Alcohol can greatly lower your blood pressure and/or increase the possibility of dizziness or fainting.
Pregnancy and breastfeeding
Pregnancy
You must inform your doctorif you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Exforge HCT before you become pregnant or as soon as you find out you are pregnant, and recommend that you take another blood pressure-lowering medicine instead. Exforge HCT is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy as it may cause serious harm to your baby when administered after this time.
Breastfeeding
Tell your doctorif you are about to start or are already breastfeeding. It has been shown that amlodipine passes into breast milk in small amounts. Exforge HCT is not recommended for use in women during breastfeeding. Your doctor may decide to prescribe a treatment that is more suitable if you want to breastfeed, especially for newborns or premature babies.
Consult your doctor or pharmacist before taking any medicine.
Driving and using machines
As with other medicines used to treat high blood pressure, you may feel dizzy, sleepy, nauseous, or have a headache. If you experience these symptoms, do not drive or use tools or machines.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor again. This will help you get the best results and reduce the risk of side effects.
The normal dose of Exforge HCT is one tabletper day.
Depending on your response to treatment, your doctor may suggest a higher or lower dose.
Do not exceed the prescribed dose.
If you take more Exforge HCT than you should
If you have accidentally taken too many Exforge HCT tablets, consult your doctor immediately. You may need medical attention. Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that can develop up to 24-48 hours after ingestion.
If you forget to take Exforge HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at the usual time. If it is almost time for the next dose, only take the next tablet at the usual time. Do nottake a double dose (two tablets at the same time) to make up for forgotten doses.
If you stop taking Exforge HCT
Stopping your treatment with Exforge HCT may cause your condition to worsen. Do not stop taking the medicine unless your doctor tells you to.
Always take this medicine, even if you feel well
Hypertensive patients often do not notice any symptoms of their problem. Many feel well. It is very important that you take this medicine exactly as your doctor has told you to get the best results and reduce the risk of side effects. Keep your appointments with your doctor even if you feel well.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
As with any combination containing three active principles, the adverse effects associated with each individual component cannot be excluded. The adverse effects observed with Exforge HCT or one of its three active principles (amlodipine, valsartan, and hydrochlorothiazide) are listed below and may occur with the use of Exforge HCT.
Some adverse effects can be serious and require immediate medical attention.
Consult your doctor immediately if, after taking this medicine, you experience any of the following serious adverse effects:
Frequent(may affect up to 1 in 10patients):
Uncommon(may affect up to 1 in 100patients):
Rare(may affect up to 1 in 1,000patients):
Very Rare(may affect up to 1 in 10,000patients):
Other adverse effects may include:
Very Frequent (may affect more than 1 in 10patients)
Frequent (may affect up to 1 in 10patients)
Uncommon (may affect up to 1 in 100patients)
Rare (may affect up to 1 in 1,000patients)
Very Rare (may affect up to 1 in 10,000patients)
Frequency Not Known (frequency cannot be estimated from available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the national reporting system included in Annex V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and blister pack (after CAD/EXP). The expiration date is the last day of the month indicated.
Do not store above 30°C.
Keep in the original packaging to protect it from moisture.
Do not use Exforge HCT if you notice that the packaging is damaged or shows signs of tampering.
Medicines should not be thrown down the drain or into the trash. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition ofExforge HCT
Exforge HCT 5mg/160mg/12.5mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.
The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica; magnesium stearate; hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171).
Exforge HCT 10mg/160mg/12.5mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.
The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica; magnesium stearate; hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
Exforge HCT 5mg/160mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.
The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).
Exforge HCT 10mg/160mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.
The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).
Exforge HCT 10mg/320mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 320 mg of valsartan, and 25 mg of hydrochlorothiazide.
The other ingredients are microcrystalline cellulose; crospovidone (type A); anhydrous colloidal silica, magnesium stearate, hypromellose (substitution type 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).
Appearance of the Product and Package Contents
The Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets are oval, white, with «NVR» on one side and «VCL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
The Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets are oval, pale yellow, with «NVR» on one side and «VDL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
The Exforge HCT 5 mg/160 mg/25 mg film-coated tablets are oval, yellow, with «NVR» on one side and «VEL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
The Exforge HCT 10 mg/160 mg/25 mg film-coated tablets are oval, brownish-yellow, with «NVR» on one side and «VHL» on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).
The Exforge HCT 10 mg/320 mg/25 mg film-coated tablets are oval, brownish-yellow, with «NVR» on one side and «VFL» on the other side. Approximate size: 19 mm (length) x 7.5 mm (width).
Exforge HCT is available in packages containing 14, 28, 30, 56, 90, 98, or 280 film-coated tablets, in multiple packages with 280 tablets (with 4 boxes, each with 70 tablets, or 20 boxes, each with 14 tablets), and in clinical packages with 56, 98, or 280 tablets in perforated dose blisters.
Not all package sizes may be marketed in your country.
Marketing Authorization Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Novartis Farma S.p.A.
Via Provinciale Schito 131
80058 Torre Annunziata (NA)
Italy
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lithuania SIA „Novartis Baltics“ Lithuanian branch Tel: +370 5 269 16 50 |
Novartis Bulgaria EOOD Tel: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tel: +32 2 246 16 11 |
Czech Republic Novartis s.r.o. Tel: +420 225 775 111 | Hungary Novartis Hungária Kft. Tel: +36 1 457 65 00 |
Denmark Novartis Healthcare A/S Tel: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Germany Novartis Pharma GmbH Tel: +49 911 273 0 | Netherlands Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Estonia SIA Novartis Baltics Estonian branch Tel: +372 66 30 810 | Norway Novartis Norge AS Tel: +47 23 05 20 00 |
Greece Novartis (Hellas) A.E.B.E. Tel: +30 210 281 17 12 | Austria Novartis Pharma GmbH Tel: +43 1 86 6570 |
Spain Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Poland Novartis Poland Sp. z o.o. Tel: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tel: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Croatia Novartis Hrvatska d.o.o. Tel: +385 1 6274 220 | Romania Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenia Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italy Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Finland Novartis Finland Oy Tel: +358 (0)10 6133 200 |
Cyprus Novartis Pharma Services Inc. Tel: +357 22 690 690 | Sweden Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvia SIA “Novartis Baltics” Tel: +371 67 887 070 | United Kingdom Novartis Pharmaceuticals UK Ltd. Tel: +44 1276 698370 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu
The average price of EXFORGE HCT 10 mg/160 mg/25 mg FILM-COATED TABLETS in November, 2025 is around 14.11 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EXFORGE HCT 10 mg/160 mg/25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.